5 results about "Plasmodium falciparum" patented technology

Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.

This invention provides a quality control product, application, and kit for the detection of Plasmodium falciparum nucleic acid. The quality control product contains an engineered Escherichia coli bacterium carrying a genetically engineered recombinant artificial chromosome. The artificial chromosome integrates a target fragment containing the full-length sequence of the Plasmodium falciparum 18S rRNA gene. The full-length sequence of the Plasmodium falciparum 18S rRNA gene is a characteristic homologous sequence of Plasmodium falciparum, as shown in SEQ ID NO:1, which is artificially designed and selected. The quality control product of this invention has better stability and is easy to store. It is not only suitable for PCR detection methods such as real-time quantitative PCR and digital PCR, but also for other types of nucleic acid detection methods, demonstrating broad applicability.

This invention discloses a type AAA ATPase VPS4 derived from Plasmodium falciparum, its encoding gene, and its applications. Based on a CRISPR-Cas9 vector that targets and knocks out this encoding gene, the protein is transformed into a bacterial strain for expression and purification to obtain high-purity recombinant PfVPS4 protein, which serves as an immunogen. The purified recombinant protein is mixed with an adjuvant and used to immunize mammals. Serum from the immunized animals is collected, and polyclonal antibodies are isolated. The polyclonal antibodies obtained in this invention exhibit high specificity, recognizing endogenous PfVPS4 protein from different strains and developmental stages. They can be used for functional studies of PfVPS4 protein levels and screening of interacting proteins, meeting various experimental needs such as gene function verification, interaction screening, and the development of detection kits. This contributes to advancing research on the ESCRT pathway and antimalarial targets in Plasmodium falciparum, and has significant scientific and commercial value.

Techniques have been developed for capturing or detecting all cancer-derived extracellular vesicles that do not depend on cancer species. A method for capturing cancer cell-derived extracellular vesicles contained in a biological sample comprises a step for bringing the biological sample into contact with the polypeptide (A), (B) or (C) described below, thereby binding the polypeptide to the cancer cell-derived extracellular vesicles. (A) A polypeptide comprising the ID1-ID2a domain of a Plasmodium falciparum-derived VAR2CSA protein (B) A polypeptide having 90% or more sequence identity with the amino acid sequence of the polypeptide (A) and capable of binding to cancer cell-derived extracellular vesicles (C) A polypeptide that is part of the polypeptide (A) or (B) and capable of binding to cancer cell-derived extracellular vesicles.

The present invention pertains to the fields of antibody technology, medicine, pharmacology, infection biology, and virology. More specifically, the present disclosure provides VHH antibodies that prevent erythrocyte entry of and infection by Plasmodium falciparum.